DEVELOPMENT OF colorectal adenocarcinoma (CRC) principally occurs via the adenoma-carcinoma sequence, a multistep process of tumor progression (Vogelstein et al. 1988) . Adenomas are much more common than adenocarcinomas and only a few will become malignant (Burgart 2002) . The important predictors of risk of developing invasive cancer from adenomas include the type and size of the adenoma and degree of dysplasia (Hamilton and Aaltonen 2000) . However, morphological features of certain adenomas alone may not provide an accurate prediction of their risk of developing into aggressive invasive carcinomas. Therefore, use of molecular biomarkers may further aid in determining risk of developing invasive cancer in these premalignant lesions, thus impacting repeat surveillance decisions.
Some of the genes known to be involved in CRC progression from an adenoma to CRC are APC, b-catenin, K-ras, c-myc, SMAD4, and p53. Of these, p53 mutations (alterations) have been proposed to occur as late carcinogenic events. The wild-type p53 induces apoptosis in response to irreversible DNA damage and to an oncogenic stimulus (Efeyan et al. 2006) , whereas mutant p53 inhibits apoptosis and confers an advantage for cell survival (Shaw et al. 1992; Lotem and Sachs 1993) . Bcl-2 protooncogene acts as an inhibitor of apoptosis (Flohil et al. 1996) . Transfection of p53 into lymphoid cells was shown to downregulate endogenous Bcl-2 expression, whereas simultaneous increase in the expression of Bax, a proapoptotic protooncogene, was observed Selvakumaran et al. 1994 ). On the other hand, p53induced cell death can be prevented by Bcl-2 expression (Hao et al. 1998) ; specifically the expression of Bcl-2 in p53-deficient mice is enhanced, with accompanying downregulation of Bax expression . These findings suggest that p53 and Bcl-2 may interact and have different roles in carcinogenesis.
Alterations in p53 and Bcl-2 were reported in early stages of CRC development (van den Berg et al. 1989; Purdie et al. 1991; Hague et al. 1994; Bosari et al. 1995; Mosnier et al. 1996; Yao et al. 1999; Krajewska et al. 2005) . Furthermore, other studies as well as our own have demonstrated that nuclear accumulation of p53 (p53 nac ) and Bcl-2 are important prognostic molecular markers specifically for a subset of patients with CRC (van den Berg et al. 1989; Purdie et al. 1991; Ofner et al. 1995; Mosnier et al. 1996; Manne et al. 1997 Manne et al. ,1998 Manne et al. ,2000 Kaklamanis et al. 1998; Yao et al. 1999) . Although multiple genetic alterations have been reported during the development of colorectal neoplasia, known molecular events that contribute to the aggressive behavior of adenomas are limited. In the present study we attempted to determine the roles of phenotypic expression of p53 nac and Bcl-2 in contiguous adenomatous components (CAdCs) of CRCs to assess the aggressive behavior of their contiguous invasive carcinomas of the colorectum.
Materials and Methods

Patients and Tissues
The institutional review boards of the University of Alabama at Birmingham (UAB) Hospital approved this study. We identified a total of 620 CRC patients from the UAB Hospital who had undergone surgical resection for first primary CRC from 1981 through 1993. We obtained the medical records including surgical pathology reports of these patients, which were reviewed by two of the gastrointestinal (GI) pathologists (CS, NCJ) to ascertain key information. During our initial selection process, those patients who died within a week of their surgery; those who had inflammatory bowel disease; those patients whose archival tissues were not available; those patients with surgical margin involvement, unspecified tumor location, multiple primaries within the colorectum, or multiple malignancies; or those patients with family or personal history of CRC were all excluded from the study population. However, based on the information in patients' charts, it may have been difficult to identify the familial vs. sporadic nature of the tumors; therefore, our patient populations can be described as Fconsecutive_ populations of CRC patients. To control for treatment bias, we included only those patients who underwent surgery as a therapeutic intervention and excluded patients who received any pre-or postsurgical therapies. Because the use of adjuvant chemotherapy was not widespread during the time frame of this study (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) , we were able to obtain a large number of CRC patients who had not received adjuvant therapy. Only 90/620 cases had CRCs with contiguous adenomatous components. We obtained formalin-fixed paraffin-embedded archival tissue blocks of these cases from the files of The UAB-Surgical Pathology Department.
In our study, two GI pathologists (CS, NCJ) reviewed hematoxylin-and eosin-stained slides of all cases to determine the histomorphological type (tubular, tubulovillous, and villous) and the degree of dysplasia of the CAdCs (Hamilton and Aaltonen 2000) . Degree of histological differentiation of CRCs was graded as well, moderate, poor or undifferentiated, as suggested by WHO (Hamilton and Aaltonen 2000) . Both pathologists were blinded to the pathological evaluations of the other; however, if there were any discrepancies they were resolved by analyzing cases together to reach a final consensus. Subsequently, we pooled well-and moderately differentiated CRCs into a low-grade group and poor and undifferentiated tumors into a high-grade group (Compton et al. 2000) . Pathological staging was performed according to the criteria of the American Joint Commission on Cancer (stages I, II, III, and IV) (Green et al. 2002) . The International Classification of Diseases for Oncology (ICD-O) codes were used to specify anatomic location of the tumor (World Health Organization 1990). Anatomic sub-sites were grouped into the proximal colon (cecum, ascending colon, and proximal two thirds of the transverse colon), the distal colon (distal one third of the transverse colon, descending colon, and sigmoid colon), and the rectum.
Patients were followed by The UAB tumor registry until their death or the date of the last documented contact within the study time frame. The tumor registries ascertain outcome (mortality) information directly from patients (or living relatives) and from the physicians of the patients through telephone and mail contacts. This information is further validated against State Death Lists. Tumor registries update follow-up information every 6 months, and follow-up of our cohort ended in April 2007.
Immunohistochemical Analysis
Five-mm tissue sections were cut from paraffin blocks representative of normal and tumor with contiguous CAdC of each case and were mounted on Superfrost/ Plus slides (Fisher Scientific; Pittsburgh, PA). We cut the tissue sections 1-2 days prior to immunostaining to avoid potential problems in antigen recognition due to storage degradation of cut tissue sections on glass slides (Prioleau and Schnitt 1995; Jacobs et al. 1996) . Immunostaining was performed as described in our earlier studies of antigen expression in different tissues (Manne et al. 1997 (Manne et al. ,2000 . In brief, sections were melted and incubated overnight at 37C prior to staining. Tissue sections were then deparaffinized in xylene and subsequently rehydrated in graded alcohols. Sections were then transferred to a Tris-buffer bath (0.05 M Tris base, 0.15 M NaCl, and 0.01% Triton X-100, pH 7.6). Microwave antigen retrieval was performed on the sections for 7 min using citrate buffer 0.01 M, pH 6 (citric acid monohydrate 2.1 g, H 2 O 1000 ml, adjusting pH with NaOH) for Bcl-2; however, no antigen retrieval was performed for tissue sections stained for p53 nac (Baas et al. 1996; Manne et al. 1997) . Each section was treated with an aqueous solution of 3% H 2 O 2 for 5 min to quench endogenous peroxidase activity. Each section was then incubated with 3% goat serum at room temperature for 1 hr to reduce nonspecific immunostaining. Tissue sections were then incubated with antihuman p53 (clone BP53-12.1, dilution 1:80; BioGenex, San Ramon, CA) and anti-human Bcl-2 (clone 124, dilution 1:60; Roche Diagnostics, Indianapolis, IN) primary monoclonal antibodies. Sections on which the primary antibody was not applied were utilized as negative controls.
Secondary detection was accomplished using a multispecies detection system (Signet Laboratories; Dedham, MA). Sections were exposed to biotinylated multispecies antibodies including anti-mouse antibodies for 20 min and then incubated with peroxidase-labeled streptavidin for 20 min. A diaminobenzidine tetrachloride supersensitive substrate kit (BioGenex) was used to visualize the antibody-antigen complex. Each section was then counterstained using hematoxylin, dehydrated using graded alcohols, and soaked in xylene before coverslipping.
The staining evaluation strategy of p53 nac and Bcl-2 expression was described in our earlier studies (Manne et al. 1997 . Slides were independently examined by three pathologists (CS, NCJ, and WEG); however, if there was a discrepancy in individual scores all three pathologists reevaluated together by reaching a consensus agreement before combining the individual scores. As described in our earlier studies (Manne et al. 1997 (Manne et al. ,2000 , we considered only tumor cells with distinct nuclear immunostaining for p53 nac as positive and considered the tumor positive only if nuclear accumulation was identified in $10% of all malignant cells in a tissue section. We chose this cut-off value of 10% positivity because this value showed the highest concordance between immunohistochemical detection of p53 nac and point mutations of the p53 gene as detected by single-strand conformational polymorphism analysis (95% of point mutations) .
A semiquantitative immunostaining score (ISS) for Bcl-2 was obtained as described previously (Manne et al. 1997 (Manne et al. ,2000 Chatla et al. 2005) . In brief, each of the three IHC reviewing pathologists estimated the proportion of cells stained and the intensity of staining in the whole tissue section. Intensity of immunostaining of individual cells was scored on a scale from 0 (no staining) to 4 (strongest intensity). In addition, each pathologist estimated the proportion of cells stained at each intensity. The percent of cells at each intensity was multiplied by the corresponding intensity value to obtain an ISS that ranged from 0 to 4. Scores of the three investigators were combined to obtain an overall mean ISS. An ISS of $0.5 was chosen as a cut-off value for Bcl-2 expression as described earlier (Manne et al. 1997 (Manne et al. ,2000 .
Results
Mean age of patients at the time of surgical resection was 66.5 years (range, 35-86 years). Based on the histopathological features, there were 53 tubular, 14 tubulovillous, and 23 villous types of CAdCs in this study. Further analysis of these histological types based on the degree of dysplasia revealed that 13/53 tubular, 2/14 tubulovillous, and 2/23 villous types were classified as CAdCs with high-grade dysplasia.
Phenotypic expression patterns of p53 nac and Bcl-2 are shown in Figure 1 . None of the adjacent normal epithelial mucosa was positive for p53 nac , but Bcl-2 expression was observed in the basal crypts. In the CAdCs and CRCs, p53 nac was localized to the nucleus and Bcl-2 to the cytoplasm. Tubular CAdCs (6/53, 11%) were less positive for p53 nac than tubulovillous (3/14, 21%) and villous CAdCs (4/23, 17%), regardless of degree of dysplasia.
Expression levels of these two makers significantly increased as one moved from adjacent normalappearing epithelium to CAdC to CRC (Figure 2) . Clinicopathological features and expression profiles of p53 nac and Bcl-2 of 90 CRCs and their CAdCs are given in Table 1 . p53 nac was observed in 13/90 (14%) CAdCs as compared with 35/90 (39%) of CRCs (Table 1) . It is interesting to note that all CAdCs with p53 nac also exhibited p53 nac in their corresponding CRCs.
Increased cytoplasmic expression of Bcl-2 was observed in 44/90 (49%) CAdCs and in 62/90 (69%) CRCs (Table 1) . Of 44 Bcl-2-expressing CAdCs, 39 (89%) showed Bcl-2 positivity in their corresponding CRCs. Only 5/90 (5.5%) cases showed loss of Bcl-2 expression in the CRCs with respect to their corresponding contiguous CAdCs, and all these cases were associated with increased expression of p53 nac (data not shown). Individual and/or concomitant expression of Bcl-2 and p53 nac did not show significant correlations with any of the prognostic features of CAdCs like grade of dysplasia, histological subtype, and extent of adenomatous component as well as the stage of their corresponding CRCs, suggesting that expression of both these markers are not dependent on these aggressive tumor features (data not shown). Table 2 shows patient characteristics and their correlation with possible combinations of p53 nac and Bcl-2 expression in CAdCs and in their corresponding CRCs.
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These correlation analyses suggested that the poor prognostic combination, p53 nac positive plus Bcl-2 negative, was predominantly observed in patients with stage III tumor; however, this association was not statistically significant. However, there was a significant association between the proximal colon site and this poor prognostic combination of p53 nac and Bcl-2 expression (x 2 p value, 0.028) (Table 2) . Also, the phenotypic expression of p53 nac and lack of Bcl-2 expression in CRCs (11/17, 65%) with adenomatous components were associated with regional lymph node involvement (data not shown).
Median survival of patients with p53 nac in both CAdCs and their corresponding CRCs was markedly lower (35.9 months) than those patients whose CAdCs were negative but their CRCs were positive for p53 nac (74.51 months) or to those patients without p53 nac in both CAdCs and CRCs (80.56 months) (Table 3) . Bcl-2 expression in these lesions did not show such a significant difference in their median survivals (Table 3) ; however, when the concomitant expression of p53 nac and Bcl-2 was considered, patients whose CAdCs were positive for p53 nac and lacked Bcl-2 expression had the lowest median survival (15.74 months) when compared with patients whose CAdCs did not demonstrate p53 nac but had increased expression of Bcl-2 (71.77 months) (Table 3) . A similar trend in survival was observed in patients whose CRCs were categorized based on these two markers (50.89 vs 77.64 months) (Table 3 ). , but its adjacent normal colonic epithelium is lacking p53 staining (thin arrow). Note the transition to p53 nac positive in the adenomatous gland in A (thick arrow). (C,E) CRCs of the matching cases of A and B exhibiting p53 nac (thick arrows); p53 nac not present in uninvolved epithelium (thin arrows). (D) CRC exhibiting p53 nac (thick arrow) and its contiguous CAdC lacking p53 staining (thin arrow). (F) Bcl-2 cytoplasmic expression in normal colonic epithelial basal crypts (thick arrow); note the strong staining in lymphocytes (thin arrow). (G,H) CAdC (G) and its contiguous CRC expressing Bcl-2 (thick arrows) (H). (I) CRC lacking Bcl-2 expression (thick arrow), but note the strong staining of Bcl-2 in lymphocytes (thin arrow).
Discussion
Our study demonstrated that the phenotypic expression levels of p53 nac and Bcl-2 significantly increased in the transition from adjacent normal-appearing epithelia to contiguous CAdCs to CRCs. CAdCs that demonstrated p53 nac continued to express p53 nac in their contiguous CRCs, and a similar pattern was observed for Bcl-2 in that reversal of phenotypes of p53 nac or Bcl-2 expression was rare. Also, even though an abnormality in p53 is considered a late event, p53 nac was present in 14% of CAdCs. A shorter survival period was observed in patients in whom their CAdCs and their contiguous CRCs exhibited p53 nac as compared with those patients with CAdCs negative and CRCs positive for p53 nac or with patients whose CAdCs and CRCs did not demonstrate p53 nac . When CAdCs were immunoreactive for p53 nac but lacked Bcl-2 expression, patients' tumors were more aggressive than those CAdCs that lacked p53 nac and increased Bcl-2 expression. These results suggest that once p53 nac has been detected and Bcl-2 is downregulated in an adenoma, its contiguous CRC behaves aggressively.
Coexistence of CAdCs in juxtaposition to CRCs supports the now well-accepted hypothesis that a subgroup of adenocarcinomas do develop from adenomas. However, only a small proportion of all adenomas progress to become invasive carcinomas (Burgart 2002) . Alterations present at the early stages are likely to play a crucial role in CRC progression. Understanding of the molecular alterations underlying this progression will aid in determining the aggressive behavior of precursor lesions as well as CRCs.
The majority of studies in CRC have demonstrated that abnormal p53, detected by IHC, is a marker of poor patient survival; however, some studies found that p53 nac has limited value in predicting clinical outcome (as reviewed in Grewal et al. 1995; Manne et al. 1997 ). Specifically, others and our own prior studies have suggested that p53 nac is a poor prognostic indicator for patients with proximal but not distal colon tumors, specifically for non-Hispanic Caucasian patients Diez et al. 2000) . In this study, 39% of CRC showed p53 nac as compared with 14% of their contiguous CAdCs. A study by Yao et al. (1999) has also demonstrated a similar incidence of p53 nac in independent villous adenomas. Low p53 nac expression in CAdCs, as compared with the juxtaposed CRCs, indicates that p53 nac is a relatively late event in colorectal carcinogenesis as demonstrated by several other studies (van den Berg et al. 1989; Purdie et al. 1991; Hague et al. 1994; Bosari et al. 1995; Mosnier et al. 1996; Yao et al. 1999; Krajewska et al. 2005 ). All cases with CAdCs demonstrating p53 nac also exhibited p53 nac in their corresponding CRCs. This finding suggests that an adenoma exhibiting p53 nac is more likely to develop into an aggressive (invasive) carcinoma.
Expression of Bcl-2 in CRC has been shown to be a favorable prognostic marker in several studies (Ofner et al. 1995; Manne et al. 1997 Manne et al. ,2000 ; Kaklamanis et al. 
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Molecular Markers of Adenomatous Components of CRC 1998; Krajewska et al. 2005) . Association of this antiapoptotic protein with patients having a better survival may be due to the ability of Bcl-2 to be converted from a protector to a killer through interactions with other proteins (Lin et al. 2004) or being related to the as yet unexplained role of Bcl-2 in suppressing cell cycle entry (Linette et al. 1996; O'Reilly et al. 1996) . As demon-strated in our earlier studies (Manne et al. 1997 (Manne et al. ,2000 , the current study also showed a higher incidence of Bcl-2 expression in CRCs (69%) than in the corresponding CAdCs (49%); however, if Bcl-2 was expressed in the CAdCs it continued to be expressed in the majority of matching CRCs. Because Bcl-2 expression is linked to a favorable prognosis, this suggests that The Journal of Histochemistry & Cytochemistry adenomas expressing Bcl-2 may similarly be tied to a favorable outcome even if CRC develops. These results suggest that Bcl-2 oncogenic protein may play a role in colorectal tumorigenesis, possibly in the early phases of the adenoma-carcinoma sequence. We conclude that the phenotypic expression of p53 and Bcl-2 progressively increased from adjacent normal-appearing epithelium to CAdC to invasive CRC. The presence of p53 nac in the CAdC is an indicator of aggressive behavior of colonic lesions, and these patients are more likely to develop aggressive invasive cancer. Although the additional prognostic pathological features including tumor budding, host responses (e.g., Crohn-like reaction), extramural invasion, vascular invasion, etc. will significantly influence the clinical outcome, evaluation of a combination of p53 and Bcl-2 expression in CAdCs correlates with patient survival. Therefore, it is of great value to assess the adenomas for the phenotypic expression of these markers, which may aid in patient follow-up and surveillance. Furthermore, these findings may lead to the development of new tools for cancer prevention.
